Cyclopharm Management

Management Kriterienprüfungen 1/4

Cyclopharm CEO ist James McBrayer , ernannt in Jun 2008, hat eine Amtszeit von 16.42 Jahren. Die jährliche Gesamtvergütung beträgt A$893.46K , bestehend aus 52.7% Gehalt und 47.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 4.78% der Aktien des Unternehmens, im Wert von A$7.75M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 6.5 Jahre bzw. 2.7 Jahre.

Wichtige Informationen

James McBrayer

Geschäftsführender

AU$893.5k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	52.7%
Amtszeit als Geschäftsführer	16.4yrs
Eigentum des Geschäftsführers	4.8%
Durchschnittliche Amtszeit des Managements	6.5yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	2.7yrs

Jüngste Management Updates

Recent updates

What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Oct 28

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Mar 02

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

Oct 22

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Jun 29

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Apr 27

Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Mar 01

Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment

Feb 07

Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?

Jan 02

We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate

Dec 06

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von James McBrayer im Vergleich zu den Einnahmen von Cyclopharm verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	-AU$9m
Mar 31 2024	n/a	n/a	-AU$7m
Dec 31 2023	AU$893k	AU$471k	-AU$5m
Sep 30 2023	n/a	n/a	-AU$6m
Jun 30 2023	n/a	n/a	-AU$7m
Mar 31 2023	n/a	n/a	-AU$7m
Dec 31 2022	AU$850k	AU$439k	-AU$7m
Sep 30 2022	n/a	n/a	-AU$5m
Jun 30 2022	n/a	n/a	-AU$4m
Mar 31 2022	n/a	n/a	-AU$4m
Dec 31 2021	AU$957k	AU$427k	-AU$5m
Sep 30 2021	n/a	n/a	-AU$5m
Jun 30 2021	n/a	n/a	-AU$4m
Mar 31 2021	n/a	n/a	-AU$5m
Dec 31 2020	AU$1m	AU$406k	-AU$6m
Sep 30 2020	n/a	n/a	-AU$6m
Jun 30 2020	n/a	n/a	-AU$6m
Mar 31 2020	n/a	n/a	-AU$4m
Dec 31 2019	AU$753k	AU$341k	-AU$3m
Sep 30 2019	n/a	n/a	-AU$3m
Jun 30 2019	n/a	n/a	-AU$2m
Mar 31 2019	n/a	n/a	-AU$1m
Dec 31 2018	AU$426k	AU$335k	-AU$35k
Sep 30 2018	n/a	n/a	-AU$409k
Jun 30 2018	n/a	n/a	-AU$782k
Mar 31 2018	n/a	n/a	-AU$1m
Dec 31 2017	AU$421k	AU$327k	-AU$2m

Vergütung im Vergleich zum Markt: JamesDie Gesamtvergütung ($USD580.59K) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Australian ($USD297.90K).

Entschädigung vs. Einkommen: JamesDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

James McBrayer (59 yo)

16.4yrs

Amtszeit

AU$893,462

Vergütung

Mr. James S. McBrayer, BSPharm, GDM, FAICD, AIM, has been the Managing Director at Cyclopharm Ltd. since June 3, 2008 and also serves as its Chief Executive Officer. Mr. McBrayer has been Company Secretary...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
James McBrayer	CEO, MD	16.4yrs	AU$893.46k	4.78% A$ 7.8m
Mathew Farag	Chief Operating Officer	7.8yrs	AU$484.33k	0.45% A$ 730.0k
Graham Phillips	Finance Manager	no data	AU$152.73k	keine Daten
Sally-Ann Cornelius	Head of Sales	5.2yrs	keine Daten	keine Daten
Niamh McAree	Head of Quality and Regulatory	5.2yrs	keine Daten	keine Daten
Chris Quinn	Head of Service	5.2yrs	keine Daten	keine Daten
Sui Cheah	Financial Controller	13.7yrs	AU$64.44k	keine Daten
Lynn McLauchlin	General Manager of Canada	no data	AU$173.42k	keine Daten
Gary Somerville	Quality & Regulatory Manager	no data	AU$151.96k	keine Daten

6.5yrs

Durchschnittliche Betriebszugehörigkeit

Erfahrenes Management: CYCDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (6.5 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
James McBrayer	CEO, MD	16.4yrs	AU$893.46k	4.78% A$ 7.8m
Dianne Angus	Independent Non-Executive Director	3.3yrs	AU$60.76k	0.020% A$ 32.6k
David Heaney	Independent Non-Executive Chairman	18yrs	AU$85.07k	0.27% A$ 439.6k
John Wigglesworth	Non-Executive Director	less than a year	keine Daten	0.049% A$ 78.8k
Kevin M. Barrow	Independent Non-Executive Director	2.2yrs	AU$60.76k	0.023% A$ 36.6k
Gregory King	Independent Non-Executive Director	2.2yrs	AU$60.76k	0.0090% A$ 14.6k

2.7yrs

Durchschnittliche Betriebszugehörigkeit

64yo

Durchschnittliches Alter

Erfahrener Vorstand: CYCDie Vorstandsmitglieder gelten nicht als erfahren ( 2.7 Jahre durchschnittliche Amtszeit), was auf einen neuen Vorstand hindeutet.

Cyclopharm Management

Management Kriterienprüfungen 1/4

Wichtige Informationen

Jüngste Management Updates

Non-Executive Director recently bought AU$51k worth of stock

Cyclopharm Limited, Annual General Meeting, May 27, 2024

Cyclopharm Limited Appoints John Wigglesworth to its Board as Non- Executive Director

CEO, MD exercised options to buy AU$402k worth of stock.

Less than half of directors are independent

Less than half of directors are independent

Recent updates

New minor risk - Market cap size

Non-Executive Director recently bought AU$51k worth of stock

Consensus revenue estimates fall by 13%

First half 2024 earnings released: AU$0.078 loss per share (vs AU$0.032 loss in 1H 2023)

Forecast breakeven date pushed back to 2026

New minor risk - Shareholder dilution

Cyclopharm Limited has completed a Follow-on Equity Offering in the amount of AUD 20.000001 million.

Cyclopharm Limited has filed a Follow-on Equity Offering in the amount of AUD 2 million.

New minor risk - Market cap size

Consensus revenue estimates fall by 14%

Cyclopharm Limited, Annual General Meeting, May 27, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Cyclopharm Limited Appoints John Wigglesworth to its Board as Non- Executive Director

Consensus EPS estimates fall by 11%

CEO, MD exercised options to buy AU$402k worth of stock.

What You Can Learn From Cyclopharm Limited's (ASX:CYC) P/SAfter Its 26% Share Price Crash

Forecast breakeven date pushed back to 2025

First half 2023 earnings released: AU$0.032 loss per share (vs AU$0.028 loss in 1H 2022)

Cyclopharm Limited Declares Unfranked Interim Dividend for the Six Months Ended June 30, 2023, Payable on 11 September 2023

Consensus estimates of losses per share improve by 13%

Is Cyclopharm Limited (ASX:CYC) Trading At A 25% Discount?

Companies Like Cyclopharm (ASX:CYC) Are In A Position To Invest In Growth

Consensus EPS estimates fall by 153%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclopharm Limited Announces Dividend for A Period of Six Months Ended December 31, 2022, Payable on April 4 2023

Less than half of directors are independent

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Less than half of directors are independent

Cyclopharm Limited Appoints Gregory King as A Non-Executive Director

Cyclopharm Limited Appoints Kevin Barrow as A Nonexecutive Director

First half 2022 earnings released: AU$0.028 loss per share (vs AU$0.045 loss in 1H 2021)

Cyclopharm Limited Declares an Unfranked Dividend for the Half Year Ended June 30, 2022, Payable on 12 September 2022

Consensus revenue estimates increase by 10%

Cyclopharm Limited Announces Independent Multicentre Study Highlights the Benefits of Technegas in Diagnosing Pulmonary Embolism in Growing Covid-19 Patient Population

Cyclopharm Limited Provides Sales Guidance for the Half Year Ended 30 June 2022

Companies Like Cyclopharm (ASX:CYC) Can Afford To Invest In Growth

Cyclopharm Limited Announces Technegas Used in Diagnosing Long COVID

Full year 2021 earnings: Revenues exceed analyst expectations

Analyst Forecasts For Cyclopharm Limited (ASX:CYC) Are Surging Higher

Here's Why We're Not At All Concerned With Cyclopharm's (ASX:CYC) Cash Burn Situation

Consensus revenue estimates increase by 14%

Forecast to breakeven in 2024

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Cyclopharm Limited Announces Dividend for Period of Six Months Ended December 31, 2021, Payable on April 12, 2022

Cyclopharm Limited Provides Earnings Guidance for the Full Year 2021

Less than half of directors are independent

We Think Cyclopharm (ASX:CYC) Can Afford To Drive Business Growth

First half 2021 earnings released: AU$0.045 loss per share (vs AU$0.074 loss in 1H 2020)

Cyclopharm Limited Provides Unaudited Revenue Guidance for the First Half of 2021

Cyclopharm Limited's (ASX:CYC) Analyst Just Slashed This Year's Estimates

Consensus revenue estimates fall to AU$16.5m

Shareholders Will Probably Hold Off On Increasing Cyclopharm Limited's (ASX:CYC) CEO Compensation For The Time Being

Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019)

Cyclopharm Limited provides Confirmation of Technegas USFDA Timetable

Analysts increase revenue estimates to AU$18.6m

Cyclopharm Limited, Annual General Meeting, May 04, 2021

Rainbows and Unicorns: The Cyclopharm Limited (ASX:CYC) Analyst Just Became A Lot More Optimistic

Full year 2020 earnings released: AU$0.079 loss per share (vs AU$0.043 loss in FY 2019)

Revenue beats expectations, earnings disappoint

Cyclopharm Limited Provides Update on USFDA Approval to Distribute Technegas in the USA in 2021

Cyclopharm (ASX:CYC) Has Rewarded Shareholders With An Exceptional 401% Total Return On Their Investment

New 90-day high: AU$3.10

Is Cyclopharm Limited (ASX:CYC) Popular Amongst Insiders?

We're Not Very Worried About Cyclopharm's (ASX:CYC) Cash Burn Rate

New 90-day high: AU$2.63

Cyclopharm Limited Announces A New Research Collaboration with Mcmasters University

New 90-day high - AU$1.59

First half earnings released

Analyse der Geschäftsführervergütung